Finerenone: Uses, Interactions, Mechanism Of Action

By Author: vasista
Total Articles: 27
Comment this article

Finerenone: Uses, Interactions, and Mechanism of Action
Chronic kidney disease (CKD), particularly in individuals with type 2 diabetes (T2D), is a major public health concern. It significantly increases the risk of cardiovascular complications, kidney failure, and early mortality. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has gained recognition for its dual renal and cardiovascular protective effects. This article explores Finerenone’s clinical uses, mechanism of action, and key drug interactions to be aware of.

What is Finerenone?
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist used to treat chronic kidney disease (CKD) associated with type 2 diabetes. It works by targeting and blocking mineralocorticoid receptors (MRs), which, when overactivated, contribute to inflammation, fibrosis, and progression of kidney and heart disease.
What distinguishes Finerenone from older MRAs like spironolactone or eplerenone is its higher selectivity and reduced hormonal side effects, making it a safer long-term option for patients with CKD and T2D.
...
... Uses of Finerenone
1. Chronic Kidney Disease in Type 2 Diabetes
The primary indication for Finerenone is slowing the progression of CKD in patients with type 2 diabetes. These patients often experience albuminuria (excess protein in urine), declining kidney function, and increased risk of cardiovascular events.
Finerenone has been shown to:
Reduce albuminuria

Slow decline in estimated glomerular filtration rate (eGFR)

Lower risk of kidney failure

Reduce the likelihood of cardiovascular events such as heart attack, stroke, and hospitalization for heart failure

It is generally used in addition to standard therapy, including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which are standard treatments for CKD and hypertension.
2. Cardiovascular Risk Reduction
Beyond kidney protection, Finerenone helps reduce cardiovascular complications in high-risk individuals. By blocking the harmful effects of aldosterone on the heart and blood vessels, Finerenone can reduce inflammation and fibrosis in the cardiovascular system.
Clinical data suggest benefits in:
Reducing left ventricular hypertrophy

Preventing heart failure hospitalizations

Lowering the risk of cardiovascular mortality in patients with CKD and diabetes

Mechanism of Action
Finerenone exerts its effect by selectively antagonizing mineralocorticoid receptors (MRs) in tissues like the kidneys, heart, and vasculature. These receptors are normally activated by aldosterone, a hormone involved in electrolyte balance and blood pressure regulation.
Pathological Role of MR Activation
In CKD and cardiovascular disease, MR activation leads to:
Sodium and water retention

Potassium excretion

Vascular inflammation

Cardiac and renal fibrosis

Oxidative stress

Finerenone blocks this pathway, reducing:
Fibrotic changes in the heart and kidneys

Inflammatory cytokine production

Proteinuria and kidney damage

Cardiac remodeling

Importantly, Finerenone does this without significant hormonal side effects, which are common with steroidal MRAs like spironolactone.
Drug Interactions
Due to its metabolic pathway and pharmacodynamic effects, Finerenone can interact with a variety of medications. Understanding these interactions is critical for safe and effective use.
1. CYP3A4 Inhibitors and Inducers
Finerenone is metabolized mainly via the CYP3A4 enzyme in the liver.
Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) can increase Finerenone levels, potentially leading to hyperkalemia and hypotension.

Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s Wort) can decrease Finerenone levels, reducing its efficacy.

2. Potassium-Elevating Agents
Since Finerenone can raise serum potassium, combining it with other potassium-sparing agents or potassium supplements increases the risk of hyperkalemia:
Potassium-sparing diuretics (e.g., amiloride, triamterene)

ACE inhibitors or ARBs (especially if potassium is already elevated)

Potassium supplements
3. NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce kidney function and potentially increase the risk of acute kidney injury when used with Finerenone, particularly in dehydrated or elderly patients.
Adverse Effects and Monitoring
While Finerenone is generally well tolerated, certain risks need to be monitored:
Common Side Effects
Hyperkalemia (most common)

Hypotension

Dizziness

Monitoring Parameters
Serum potassium: Check before initiation, and regularly during treatment

eGFR: Assess kidney function before and during therapy

Blood pressure: Monitor for hypotension

Finerenone should not be initiated in patients with:
Serum potassium >5.0 mmol/L

eGFR